Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:424509.
doi: 10.1155/2014/424509. Epub 2014 Jul 14.

Identifying the gene signatures from gene-pathway bipartite network guarantees the robust model performance on predicting the cancer prognosis

Li He  1 , Yuelong Wang  2 , Yongning Yang  2 , Liqiu Huang  2 , Zhining Wen  2
Affiliations

Identifying the gene signatures from gene-pathway bipartite network guarantees the robust model performance on predicting the cancer prognosis

Li He et al. Biomed Res Int. 2014.

Abstract

For the purpose of improving the prediction of cancer prognosis in the clinical researches, various algorithms have been developed to construct the predictive models with the gene signatures detected by DNA microarrays. Due to the heterogeneity of the clinical samples, the list of differentially expressed genes (DEGs) generated by the statistical methods or the machine learning algorithms often involves a number of false positive genes, which are not associated with the phenotypic differences between the compared clinical conditions, and subsequently impacts the reliability of the predictive models. In this study, we proposed a strategy, which combined the statistical algorithm with the gene-pathway bipartite networks, to generate the reliable lists of cancer-related DEGs and constructed the models by using support vector machine for predicting the prognosis of three types of cancers, namely, breast cancer, acute myeloma leukemia, and glioblastoma. Our results demonstrated that, combined with the gene-pathway bipartite networks, our proposed strategy can efficiently generate the reliable cancer-related DEG lists for constructing the predictive models. In addition, the model performance in the swap analysis was similar to that in the original analysis, indicating the robustness of the models in predicting the cancer outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The gene-pathway bipartite network constructed with 29 gene signatures that were used for predicting the reoperative treatment response of breast cancer.
Figure 2
Figure 2
The gene-pathway bipartite network constructed with 50 gene signatures that were used for predicting the overall survival milestone outcome of acute myeloma leukemia.
Figure 3
Figure 3
The gene-pathway bipartite network constructed with 62 gene signatures that were used for predicting the molecular subclasses of high-grade glioblastoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536. - PubMed
    1. Leung EL, Cao Z-W, Jiang Z-H, Zhou H, Liu L. Network-based drug discovery by integrating systems biology and computational technologies. Briefings in Bioinformatics. 2013;14(4):491–505. - PMC - PubMed
    1. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99(5):1745–1757. - PubMed
    1. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Journal of Clinical Oncology. 2006;24(26):4236–4244. - PubMed
    1. Shaughnessy JD, Jr., Zhan F, Burington BE, et al. Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–2284. - PubMed

Publication types

Substances